The Autism Biomarkers Consortium for Clinical Trials: Study Design and Progress to Interim Analysis
J. McPartland1, S. J. Webb2, F. Shic3, A. Naples4, C. Sugar5, M. Murias6, J. Dziura7, C. Brandt7, R. A. Bernier2, K. Chawarska8, G. Dawson9, S. Faja10, S. Jeste11 and C. A. Nelson12, (1)Yale Child Study Center, Yale Child Study Center, New Haven, CT, (2)Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, (3)Center for Child Health, Behavior and Development, Seattle Children's Research Institute, Seattle, WA, (4)Yale Child Study Center, Yale University School of Medicine, New Haven, CT, (5)University of California, Los Angeles, Los Angeles, CA, (6)Duke Center for Autism and Brain Development, Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, (7)Yale University, New Haven, CT, (8)Child Study Center, Yale University School of Medicine, New Haven, CT, (9)Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, (10)Boston Children's Hospital / Harvard Medical School, Boston, MA, (11)Children's Hospital Los Angeles, Los Angeles, CA, (12)Department of Developmental Medicine, Boston Children's Hospital, Boston, MA